Nimodipine on the clinical course of patients with acute ischemic stroke

Completed

Phase N/A Results

Results

Comparison of the Mathew sum scores in the standard group with those of the nimodipine group (analysis of variance) revealed a highly significant difference (P< 0.0001) in favor of nimodipine during the 4 week period of treatment. Based on the individual items of the Mathew scale, the level of consciousness at days 3 and 5 and disability at days 7, 14, and 21 were significantly improved under the nimodipine-therapy.